Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2023 Filed Apr 3, 2023 22:23 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $40.80 | $163.20 |
DisclosureSEC source: 0001225208-23-004400 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,814 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 12:03 UTC |
Echevarria JosephDirector
|
GrantPhantom Stock Units · Derivative | 1,133.578 | $40.80 | $46,249.98 |
DisclosureSEC source: 0001225208-23-004406 · doc4.xml · derivative · entry 1 Echevarria Joseph · CIK 0001633137 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,800.61 Underlying: Common Stock · 1,133.578 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 12:03 UTC |
NARAYEN SHANTANUDirector
|
GrantPhantom Stock Units · Derivative | 1,225.49 | $40.80 | $49,999.99 |
DisclosureSEC source: 0001225208-23-004407 · doc4.xml · derivative · entry 1 NARAYEN SHANTANU · CIK 0001224154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,145.208 Underlying: Common Stock · 1,225.49 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 12:03 UTC |
Quincey JamesDirector
|
GrantPhantom Stock Units · Derivative | 949.755 | $40.80 | $38,750.00 |
DisclosureSEC source: 0001225208-23-004408 · doc4.xml · derivative · entry 1 Quincey James · CIK 0001561264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,245.893 Underlying: Common Stock · 949.755 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 12:03 UTC |
SMITH JAMES CDirector
|
GrantPhantom Stock Units · Derivative | 1,102.941 | $40.80 | $44,999.99 |
DisclosureSEC source: 0001225208-23-004409 · doc4.xml · derivative · entry 1 SMITH JAMES C · CIK 0001611777 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,506.042 Underlying: Common Stock · 1,102.941 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| March 17, 2023 Filed Mar 17, 2023 23:19 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
OtherPhantom Stock Units SSP · Derivative | 74,813 | $40.10 | $3,000,001.30 |
DisclosureSEC source: 0001225208-23-004110 · doc4.xml · derivative · entry 2 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,790 Underlying: Common Stock · 74,813 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · shares: This transaction constitutes an intra-plan transfer to acquire Pfizer stock units in the Pfizer stock unit fund under the Pfizer Inc. Supplemental Savings Plan. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 13:28 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
OtherPhantom Stock Units SSP · Derivative | 24,938 | $40.10 | $1,000,013.80 |
DisclosureSEC source: 0001225208-23-004144 · doc4.xml · derivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,860 Underlying: Common Stock · 24,938 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: This transaction constitutes an intra-plan transfer to acquire Pfizer stock units in the Pfizer stock unit fund under the Pfizer Inc. Supplemental Savings Plan. F3 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F3 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:53 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 451 | $40.28 | $18,166.28 |
DisclosureSEC source: 0001225208-23-004094 · doc4.xml · derivative · entry 3 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,176 Underlying: Common Stock · 451 shares Expires not disclosed F2 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F3 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:53 UTC |
DAMICO JENNIFER B.SVP & Controller
|
SaleCommon Stock | 9,912 | $40.02 | $396,678.24 |
DisclosureSEC source: 0001225208-23-004094 · doc4.xml · nonDerivative · entry 2 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,003 Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:53 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 78 | $40.28 | $3,141.84 |
DisclosureSEC source: 0001225208-23-004095 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,810 Underlying: Common Stock · 78 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 23:19 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 1,335 | $40.28 | $53,773.80 |
DisclosureSEC source: 0001225208-23-004110 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,977 Underlying: Common Stock · 1,335 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:52 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Tax withholdingCommon Stock | 1,427 | $40.78 | $58,193.06 |
DisclosureSEC source: 0001225208-23-002986 · doc4.xml · nonDerivative · entry 4 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,275 F6 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:52 UTC |
McDermott MichaelExecutive Vice President
|
Tax withholdingCommon Stock | 3,081 | $40.78 | $125,643.18 |
DisclosureSEC source: 0001225208-23-002987 · doc4.xml · nonDerivative · entry 4 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,874 F6 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:53 UTC |
SAHNI PAYALExecutive Vice President
|
Tax withholdingCommon Stock | 1,297 | $40.78 | $52,891.66 |
DisclosureSEC source: 0001225208-23-002988 · doc4.xml · nonDerivative · entry 4 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,077 F6 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 13:24 UTC |
Dolsten MikaelPresident R&D
|
Tax withholdingCommon Stock | 37,078 | $41.75 | $1,548,006.50 |
DisclosureSEC source: 0001225208-23-002917 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,145 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). F2 · price: Price is the closing price of Pfizer common stock on February 24, 2023. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 13:24 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 43,419 | $41.75 | $1,812,743.25 |
DisclosureSEC source: 0001225208-23-002918 · doc4.xml · nonDerivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,058 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). F2 · price: Price is the closing price of Pfizer common stock on February 24, 2023. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 13:24 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 26,389 | $41.75 | $1,101,740.75 |
DisclosureSEC source: 0001225208-23-002919 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,146 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). F2 · price: Price is the closing price of Pfizer common stock on February 24, 2023. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 33,654 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-23-002983 · doc4.xml · derivative · entry 5 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,654 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 14,966 | $43.44 | $650,123.04 |
DisclosureSEC source: 0001225208-23-002983 · doc4.xml · nonDerivative · entry 3 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,637 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 7,870 | $41.75 | $328,572.50 |
DisclosureSEC source: 0001225208-23-002983 · doc4.xml · nonDerivative · entry 2 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,603 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 24, 2023. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionCommon Stock | 33,654 | $22.89 | $770,340.06 |
DisclosureSEC source: 0001225208-23-002983 · doc4.xml · nonDerivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
Hwang AngelaPresident, Global Biopharma
|
Exercise / conversionStock Appreciation Rights · Derivative | 20,273 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-23-002984 · doc4.xml · derivative · entry 6 Hwang Angela · CIK 0001725474 · President, Global Biopharma 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,273 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
Hwang AngelaPresident, Global Biopharma
|
Tax withholdingCommon Stock | 9,015 | $43.44 | $391,611.60 |
DisclosureSEC source: 0001225208-23-002984 · doc4.xml · nonDerivative · entry 3 Hwang Angela · CIK 0001725474 · President, Global Biopharma 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,778 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
Hwang AngelaPresident, Global Biopharma
|
Tax withholdingCommon Stock | 5,748 | $41.75 | $239,979.00 |
DisclosureSEC source: 0001225208-23-002984 · doc4.xml · nonDerivative · entry 2 Hwang Angela · CIK 0001725474 · President, Global Biopharma 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,793 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 24, 2023. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
Hwang AngelaPresident, Global Biopharma
|
Exercise / conversionCommon Stock | 20,273 | $22.89 | $464,048.97 |
DisclosureSEC source: 0001225208-23-002984 · doc4.xml · nonDerivative · entry 1 Hwang Angela · CIK 0001725474 · President, Global Biopharma 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Exercise / conversionStock Appreciation Rights · Derivative | 11,150 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-23-002986 · doc4.xml · derivative · entry 5 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,150 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Tax withholdingCommon Stock | 4,958 | $43.44 | $215,375.52 |
DisclosureSEC source: 0001225208-23-002986 · doc4.xml · nonDerivative · entry 3 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,702 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Tax withholdingCommon Stock | 2,233 | $41.75 | $93,227.75 |
DisclosureSEC source: 0001225208-23-002986 · doc4.xml · nonDerivative · entry 2 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,660 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 24, 2023. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Exercise / conversionCommon Stock | 11,150 | $22.89 | $255,223.50 |
DisclosureSEC source: 0001225208-23-002986 · doc4.xml · nonDerivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 72,984 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-23-002985 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,984 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 32,455 | $43.44 | $1,409,845.20 |
DisclosureSEC source: 0001225208-23-002985 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,311 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 22,413 | $41.75 | $935,742.75 |
DisclosureSEC source: 0001225208-23-002985 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,766 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 24, 2023. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionCommon Stock | 72,984 | $22.89 | $1,670,603.76 |
DisclosureSEC source: 0001225208-23-002985 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
McDermott MichaelExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 14,178 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-23-002987 · doc4.xml · derivative · entry 5 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,178 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
McDermott MichaelExecutive Vice President
|
Tax withholdingCommon Stock | 6,305 | $43.44 | $273,889.20 |
DisclosureSEC source: 0001225208-23-002987 · doc4.xml · nonDerivative · entry 3 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,955 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
McDermott MichaelExecutive Vice President
|
Tax withholdingCommon Stock | 2,839 | $41.75 | $118,528.25 |
DisclosureSEC source: 0001225208-23-002987 · doc4.xml · nonDerivative · entry 2 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,260 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 24, 2023. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:52 UTC |
McDermott MichaelExecutive Vice President
|
Exercise / conversionCommon Stock | 14,178 | $22.89 | $324,534.42 |
DisclosureSEC source: 0001225208-23-002987 · doc4.xml · nonDerivative · entry 1 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:53 UTC |
SAHNI PAYALExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 8,921 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-23-002988 · doc4.xml · derivative · entry 6 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,921 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:53 UTC |
SAHNI PAYALExecutive Vice President
|
Tax withholdingCommon Stock | 3,967 | $43.44 | $172,326.48 |
DisclosureSEC source: 0001225208-23-002988 · doc4.xml · nonDerivative · entry 3 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,374 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:53 UTC |
SAHNI PAYALExecutive Vice President
|
Tax withholdingCommon Stock | 1,786 | $41.75 | $74,565.50 |
DisclosureSEC source: 0001225208-23-002988 · doc4.xml · nonDerivative · entry 2 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,341 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 24, 2023. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 22:53 UTC |
SAHNI PAYALExecutive Vice President
|
Exercise / conversionCommon Stock | 8,921 | $22.89 | $204,201.69 |
DisclosureSEC source: 0001225208-23-002988 · doc4.xml · nonDerivative · entry 1 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2023 Filed Mar 17, 2023 20:53 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Tax withholdingCommon Stock | 360 | $41.75 | $15,030.00 |
DisclosureSEC source: 0001225208-23-004094 · doc4.xml · nonDerivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,383 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:11 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 359,681 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002808 · doc4.xml · derivative · entry 4 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,681 Underlying: Common Stock · 359,681 shares Expires 2030-02-23 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:11 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 413,280 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002808 · doc4.xml · derivative · entry 3 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,280 Underlying: Common Stock · 413,280 shares Expires 2028-02-23 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:14 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantStock Appreciation Rights · Derivative | 10,591 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002809 · doc4.xml · derivative · entry 7 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,591 Underlying: Common Stock · 10,591 shares Expires 2030-02-23 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:14 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantStock Appreciation Rights · Derivative | 12,169 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002809 · doc4.xml · derivative · entry 6 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,169 Underlying: Common Stock · 12,169 shares Expires 2028-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:14 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantCommon Stock | 3,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002809 · doc4.xml · nonDerivative · entry 4 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,743 F5 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:17 UTC |
Denton David MChief Financial Officer & EVP
|
GrantStock Appreciation Rights · Derivative | 89,920 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002810 · doc4.xml · derivative · entry 3 Denton David M · CIK 0001428718 · Chief Financial Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,920 Underlying: Common Stock · 89,920 shares Expires 2030-02-23 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:17 UTC |
Denton David MChief Financial Officer & EVP
|
GrantStock Appreciation Rights · Derivative | 103,320 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002810 · doc4.xml · derivative · entry 2 Denton David M · CIK 0001428718 · Chief Financial Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,320 Underlying: Common Stock · 103,320 shares Expires 2028-02-23 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:18 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 119,894 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002811 · doc4.xml · derivative · entry 4 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,894 Underlying: Common Stock · 119,894 shares Expires 2030-02-23 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.